ImmunArray

Company Overview

Snapshot

Founded in January 2006 by Irun Cohen, ImmunArray operated with 1–10 employees. The company raised a total of $15.5 million across 5 funding rounds from 4 investors. In August 2019, ImmunArray was acquired by Salveo Diagnostics.

Business overview

ImmunArray develops in-vitro diagnostic tests utilizing its iCHIP microarray technology platform. This technology mines immune system repertoires to provide insights into an individual's immune profile, focusing on auto-antibody repertoires from blood samples. The company's products support personalized medicine approaches, with an initial focus on diagnostic, prognostic, and therapeutic guidance for autoimmune diseases and transplantation medicine. ImmunArray also develops markers for traumatic brain injury. The company operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology, and Test Diagnostics & Screening, serving healthcare providers and laboratories in the United States and Europe.

Strategic signal

In November 2018, ImmunArray appointed a new CEO, while the former CEO transitioned to lead a spin-off venture. This leadership change signaled a strategic realignment for the company, potentially indicating a renewed focus on core operations or a pivot in its long-term development strategy ahead of its acquisition.

Company Intelligence Q&A

What was a significant corporate development for ImmunArray in 2019?

In August 2019, ImmunArray was acquired by Salveo Diagnostics, leading to the cessation of its operations.

What was a key partnership established by ImmunArray?

In July 2017, ImmunArray entered into a partnership with Kindstar Global to expand its diagnostic testing services in China, focusing on autoimmune disease detection.

What was a notable leadership change at ImmunArray?

In November 2018, ImmunArray appointed a new CEO, while the former CEO moved to lead a spin-off venture.